The Southeast Asian nation is battling a third coronavirus wave with the highest number of daily cases and deaths reported since the start of the pandemic, raising public concerns of adequate access to vaccines.
On Tuesday, Thailand reported 2,662 new Covid-19 cases and 28 deaths, according to its Covid-19 task force (CCSA).
Thailand plans to administer 6 million shots in June using the AstraZeneca and Sinovac vaccines, according to the country’s Public Relations department.
In the capital, Bangkok, on Monday, 25 vaccination stations were set up outside hospitals, malls, subway stations, gymnasiums, gas stations and university campuses.
Thailand’s Prime Minister Prayut Chan-o-cha last month set a target of 100 million vaccine doses to be administered by the end of the year. Most of those — 61 million — are expected to be AstraZeneca doses produced locally by royal-owned company Siam BioScience.
The country has faced criticism from opposition leaders for being overly reliant on one supplier and over concerns of a lack of supply. Thailand wants to vaccinate 70% of the population by the end of the year, but so far only about 4% of its 69 million people have received at least one dose.
AstraZeneca is working with Siam BioScience to produce and distribute vaccines across Southeast Asia. The vaccine will be ready for export to other countries in the region in July, a news release said.
Observing the rollout outside Bangkok’s Bang Sue Grand Station, Prime Minister Prayut sought to reassure the public there would be enough vaccines.
“People are concerned about Covid-19 vaccine arrangement. The government has not been ignoring that, concerned offices have been instructed to urgently negotiate to find more vaccines to every willing Thai,” he said.
Negotiations are ongoing for 20 million doses from Pfizer/BioNTech and 5 millions doses from Johnson & Johnson, according to a post on the government’s Facebook page.
But questions over public transparency and whether Siam BioScience can meet its production targets is a sensitive issue in Thailand. Founded in 2009, the biopharmaceuticals manufacturer is solely owned by King Maha Vajiralongkorn and has not made vaccines before.
Thailand has some of the strictest lese majeste laws in the world where criticizing the king, queen, or heir apparent can result in a 15-year prison sentence.
In March, opposition politician Thanathorn Juangroongruangkit was charged with defaming the monarchy after he questioned the selection of Siam BioScience as the main supplier of Thailand’s vaccine drive.
Police said Thanathorn had committed lese majeste in a Facebook Live stream during which he said the government had mishandled the vaccine campaign and given an unfair advantage to Siam BioScience, according to Progressive Movement, the group headed by Thanathorn.
CNN has reached out to Siam BioScience for comment. Speaking to local media the Standard, Nualphan Lamsam, honorary director of corporate communications at Siam BioScience defended the company and said there was no delay in delivering the vaccine.
Thailand’s disease control department said as of June 7 there were 2.04 million AstraZeneca doses and 1.5 million Sinovac doses available in the country.
The department said it expected to receive 3.43 million more doses by the end of June.
Though it began its mass rollout on Monday, Thailand started vaccinating medical staff and frontline workers on February 28. As of June 4, more than 4 million doses were administered, including 1 million doses in Bangkok, it said.
As of Tuesday, Thailand had reported a total of 182,548 Covid-19 cases and 1,297 deaths, according to the country’s health ministry.